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Abstract 
Positron emission tomography (PET) using radiolabeled biomolecules is a translational molecular 
imaging technology that is increasingly used in support of drug development. Current methods for 
radiolabeling biomolecules with fluorine-18 are laborious and require multistep procedures with 
moderate labeling yields. The Al18F-labeling strategy involves chelation in aqueous medium of aluminum 
mono[18F]fluoride ({Al18F}2+) by a suitable chelator conjugated to a biomolecule. However, the need for 
elevated temperatures (100-120 °C) required for the chelation reaction limits its widespread use. 
Therefore, we designed a new restrained complexing agent (RESCA) for application of the AlF strategy 
at room temperature. 
Methods. The new chelator RESCA was conjugated to three relevant biologicals and the constructs 
were labeled with {Al18F}2+ to evaluate the generic applicability of the one-step Al18F-RESCA-method. 
Results. We successfully labeled human serum albumin with excellent radiochemical yields in less than 
30 minutes and confirmed in vivo stability of the Al18F-labeled protein in rats. In addition, we efficiently 
labeled nanobodies targeting the Kupffer cell marker CRIg, and performed µPET studies in healthy and 
CRIg deficient mice to demonstrate that the proposed radiolabeling method does not affect the 
functional integrity of the protein. Finally, an affibody targeting HER2 (PEP04314) was labeled 
site-specifically, and the distribution profile of (±)-[18F]AlF(RESCA)-PEP04314 in a rhesus monkey was 
compared with that of [18F]AlF(NOTA)-PEP04314 using whole-body PET/CT. 
Conclusion. This generic radiolabeling method has the potential to be a kit-based fluorine-18 labeling 
strategy, and could have a large impact on PET radiochemical space, potentially enabling the 
development of many new fluorine-18 labeled protein-based radiotracers. 
Key words: Al18F-labeling; PET; human serum albumin; nanobody; affibody. 
Introduction 
Positron emission tomography (PET) provides 
non-invasive, sensitive and specific imaging of 
molecular interactions in vivo, and can be used to 
study the function of cells, receptors, 
neurotransmitters, genes and drug pharmacokinetics 
[1]. Among positron-emitting radioisotopes, the 
halogen fluorine-18 is the most commonly used 
radionuclide due to its optimal chemical properties 
and favorable nuclear decay characteristics [2]. The 
low maximum positron energy (0.635 MeV) of 
fluorine-18 enables the acquisition of high resolution 
PET images as a result of the short range of tissue 
penetration prior to annihilation [3, 4]. Fluorine-18 has 
a half-life of 109.8 min, which is short enough to avoid 
prolonged irradiation of subjects, yet still long enough 
to allow extended in vivo investigations and 
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distribution to remote imaging centres without an 
on-site cyclotron [2, 5]. The success and medical 
impact of PET using 2-[18F]fluoro-2-deoxy-D-glucose 
([18F]FDG), led to a fast worldwide proliferation of 
PET camera’s and fluorine-18 producing cyclotron 
centres [6]. Consequently, fluorine-18 is now readily 
available in numerous hospitals and research centres, 
and the infrastructure is in place to expand its 
application far beyond [18F]FDG [7]. 
In addition to using small organic molecules, 
researchers in the molecular imaging community are 
increasingly interested in using peptides and high 
molecular weight biomolecules for use as 
PET-radiopharmaceuticals, in line with the growth of 
the share of biologic- based drugs in the global 
pharmaceutical market [8]. The molecular imaging 
technique, immuno-PET, combines the high in vivo 
target affinity and selectivity of antibodies or 
antibody fragments and the high resolution and 
sensitivity of PET for imaging ligand-target 
interactions. An immuno-PET tracer should exhibit a 
high target-to-background ratio, high target 
specificity, high stability, sufficient solubility and low 
immunogenicity [9]. The advantage of using mAbs 
(150 kDa) as vector molecules in immuno-PET is their 
(sub)nanomolar affinity, excellent specificity and high 
accumulation at the target site [10]. Moreover, the 
availability of a large number of FDA-approved mAbs 
for imaging purposes can stimulate clinical 
translation [9]. However, as a result of the long 
residence time in blood of full-length antibodies, 
imaging with sufficient contrast between target and 
non-target tissues can only be performed several days 
post-injection, with peak contrast generally obtained 
after 2-4 days. Hence, due to the slow kinetics, 
radiolabeling with long-lived radionuclides such as 
zirconium-89 (89Zr, t1/2: 3.3 days) or iodine-124 (124I, 
t1/2: 4.2 days) is required, causing a high radiation 
burden for the patient (20-40 mSv per scan). The use 
of long-lived radionuclides is impractical for routine 
clinical use and, moreover, has a severe social impact 
on patients as only limited visiting time of family is 
advised for radioprotection reasons.  
Advancements in biotechnology have led to the 
bioengineering of many vector molecules with shorter 
biological half-lives, and compatible with a 
short-lived PET radionuclide such as fluorine-18, that 
can be used as an alternative to mAbs [11]. Examples 
of suitable vector molecules are 80-kDa minibodies 
[12], 55-kDa antigen-binding fragments (Fab) [13], 
28-kDa single-chain variable fragment (scFv) [14], 
18-kDa designed ankyrin repeat proteins (DARPins) 
[15], 15-kDa antibody fragments derived from 
heavy-chain only antibodies (VHH or nanobodies) [16], 
7-kDa affibody molecules [17], 7-kDa 
albumin-binding domain derived affinity proteins 
(ADAPTs) [18] and many others [11]. These 
radiolabeled vector molecules are expected to play an 
increasingly important role in cancer diagnosis, 
treatment selection, and monitoring of molecularly 
targeted therapeutics. However, the incorporation of 
fluorine-18 into heat-sensitive and complex 
biomolecules creates substantial challenges for 
radiochemists, and so only a limited number of 
methods are currently available.  
Conventional radiofluorination strategies 
involve carbon-fluorine bond formation in anhydrous 
aprotic solvents using aliphatic or aromatic 
nucleophilic substitution reactions, generally at high 
temperatures (Figure 1A). A solution to overcome the 
complications caused by the low nucleophilicity of 
[18F]F- in aqueous media is the use of prosthetic 
groups (Figure 1B). Fluorine-18 labeled prosthetic 
groups (or secondary labeling agents) are small and 
simple fluorine-18 containing molecules that facilitate 
the radiolabeling process of complex molecules [19]. 
Some well-known prosthetic groups are 
N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) [20], 
6-[18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl 
ester ([18F]F-Py-TFP) [21] and N-[2-(4-[18F]fluoroben-
zamido)ethyl]maleimide ([18F]FBEM) [22]. This 
approach avoids exposing the biomolecule to harsh 
conditions, but intrinsically requires time-consuming 
synthetic procedures that often include several 
purification steps (e.g. HPLC). Hence, there is a need 
for innovative, efficient radiolabeling methods that 
will boost the use of fluorine-18 labeled biomolecules 
in PET research and clinical studies.  
Several non-carbon elements favour strong 
bonds (i.e. high bond enthalpy) with fluorine, with 
preservation of high kinetic stability of the fluorine 
containing compounds formed. Moreover, lower 
activation energy is required for formation of these 
bonds in comparison to carbon-fluorine bonds [8]. 
This has been the basis for a new research field in 
18F-radiochemistry. Currently, boron, silicon and 
aluminum are being investigated as elements 
allowing fluorination in an aqueous environment. An 
excellent review by Bernard-Gauthier et al. deals with 
the current status of both the 18F-SiFA and 18F-BF3 
technologies for fluorine-18 labeling, and their use in 
preclinical PET imaging [23]. The strength of the 
inorganic approach is that it can entail a single, 
potentially very fast, radiochemical reaction step in, at 
least partially, aqueous media [8], that can be easily 
automated for routine production. 
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Figure 1. Overview of fluorine-18 radiolabeling methods for heat-sensitive biomolecules A: Conventional radiofluorination strategies in anhydrous 
aprotic solvents using aliphatic or aromatic nucleophilic substitution reactions at high temperatures are not compatible with heat-sensitive biomolecules B: 
Fluorine-18 labeled prosthetic groups facilitate the radiolabeling process of complex molecules. This approach avoids exposing the biomolecule to harsh conditions 
but intrinsically requires a time consuming synthetic procedure to obtain the radiolabeled prosthetic group that often includes several purification steps C: One-pot 
radiolabeling of biomolecules with fluorine-18 via the Al18F-method at 110 °C using macrocyclic Al18F-chelators (not compatible with heat-sensitive biomolecules) or 
at room temperature using a restrained complexing agent (RESCA) as Al18F-chelator. 
 
Al18F-chelation is a relatively new strategy that 
allows one-pot radiofluorination of biomolecules in 
aqueous media [24]. In this method, fluorine is firmly 
bound to Al3+ (>670 KJ/mol), forming aluminum 
mono[18F]fluoride ([18F]{AlF}2+), and this moiety is 
subsequently chelated by a suitable chelator 
conjugated to a biomolecule (Figure 1C) [25].  
A wide range of peptides have been labeled 
using the Al18F-method with macrocyclic chelators 
such as the pentadentate (N3O2-donor) ligand 
1,4,7-triazacyclononane-1,4-diacetate (NODA) and the 
hexadentate (N3O3-donor) ligand 1,4,7-triazacyclo-
nonane-1,4,7-triacetate (NOTA) [26]. This has allowed 
radiolabeling with [18F]{AlF}2+ of relatively small 
peptides such as αvβ3 integrin-binding peptides [27], 
and also larger peptides, such as exendin-4 [28] and 
affibodies [29]. The first clinical study using peptides 
labeled via the Al18F-method was published in 2013 
[30]. Although the macrocyclic chelators used in these 
methods have shown a lot of potential, the approach 
has limited applicability due to the high temperature 
required for the complexation reaction (≥ 100 °C) [31]. 
These harsh reaction conditions are clearly not 
compatible with heat-sensitive biomolecules (Figure 
1C).  
Recently, we developed a new restrained 
complexing agent, ((±)-H3RESCA), that allows 
efficient chelation of [18F]{AlF}2+ using mild labeling 
conditions. (±)-H3RESCA is an acyclic pentadentate 
ligand with an N2O3 coordinative set of donor atoms. 
As a result, (±)-H3RESCA showed excellent labeling 
properties at room temperature and its Al18F-complex 
demonstrated high in vitro and in vivo stability. 
Indeed, the development of this new chelator makes it 
possible to radiolabel heat-sensitive biomolecules 
with fluorine-18 in one radiolabeling step (Figure 1C). 
The synthesis of this new chelator, in addition to the 
synthesis of bifunctional derivatives, in depth 
characterization of the corresponding Al18F-complex, 
and evaluation of in vitro and in vivo stability of the 
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Al18F-complex, is described in a patent [32] and will 
be reported elsewhere. Here we demonstrate the 
generic potential of the Al18F-RESCA-method by 
labeling human serum albumin, a nanobody targeting 
the Kupffer cell marker CRIg, and an affibody 
targeting HER2 (PEP04314).  
Materials and Methods 
General 
All reagents and solvents were purchased from 
Sigma-Aldrich (Bornem, Belgium), Fluka (Bornem, 
Belgium), Fisher (Doornik, Belgium) or Acros 
Organics (Geel, Belgium). The synthesis of 
(±)-H3RESCA and synthesis of bifunctional 
derivatives is described in patent WO/2016/065435 
[32]. All buffers used for derivatization and labeling 
of proteins were chelexed (chelex, 100 sodium form 
(Sigma Aldrich), 2 g/l, 30 min stirring at rt and 
filtration with a 0.45 µm polyamide filter (Sartorius 
Stedim Biotech, Göttingen, Germany)). Fluorine-18 
was produced on site using a cyclotron (IBA Cyclone 
18/9, IBA, Louvain-la-Neuve, Belgium) by irradiation 
of H218O with 18-MeV protons. Radioactivity was 
measured using an ionization chamber-based activity 
meter (Capintec Radioisotope Calibrator CRC-721, 
Ramsey, NJ, USA).  
A Dionex Ultimate 3000 UPLC System (Thermo 
Fisher Scientific, Sunnyvale, USA) coupled in series to 
a UV detector, a 3-inch NaI(Tl) radioactivity detector, 
and an ultra-high resolution time-of-flight mass 
spectrometer with electron spray ionization (ESI) 
(MaXis Impact, Bruker, Bremen, Germany) was used 
for analysis of human serum albumin and nanobody 
constructs. For HSA, a massPREP on-line desalting 
cartridge (2.1 mm x 10 mm, Waters, Milford, USA) 
was applied using the following method. Solvent A 
(H2O, 0.1% HCOOH) and solvent B (acetonitrile, 0.1% 
HCOOH), flow rate 0.4 ml/min. The elution gradient 
was: 0-1 min: 95% A; 1-3 min: from 95% A to 20% A; 
3-5 min: 95% A. For nanobody constructs, a Zorbax 
SB-C3 column (1.8 µm, 3.0 mm x 100 mm, Agilent) 
was used with following gradient for 
(radio)-LC-HRMS: Solvent A (H2O, 0.1% HCOOH) 
and solvent B (acetonitrile, 0.1% HCOOH), flow rate 
0.3 ml/min. The elution gradient was: 0-1 min: 99% A; 
1-7 min: from 99% A to 1% A; 7-10 min: 1% A; 10.1-12 
min: 99% A. UV monitoring of the eluate was 
performed at 280 nm. For deconvolution analysis of 
the raw mass spectral data, the software program 
DataAnalysis (Bruker Daltonik, Bremen, Germany) 
was used. Calculated average neutral molecular ion 
mass values were obtained using Compas Isotope 
Pattern (version 3.2, Bruker) software.  
Autoradiography was performed using 
phosphor storage screens (super-resolution screen, 
Perkin Elmer, Waltham, USA). Screens were read in a 
Cyclone Plus system (Perkin Elmer), and images were 
analyzed using Optiquant software (Perkin Elmer). 
Size-exclusion chromatography (SEC) was carried out 
with a system consisting of a Merck-Hitachi L-6200 
pump and a Merck Hitachi L-4200 UV-VIS detector 
coupled in series to a 3-inch NaI(Tl) radioactivity 
detector on a Superdex 200 10/300 GL column (for 
HSA constructs), or on a Superdex 75 10/300 GL 
column (for nanobody constructs) (GE Healthcare 
Bio-Science AB, Uppsala, Sweden) using sodium 
phosphate buffer (0.01 M, pH 7.4, 0.14 M NaCl), as 
eluent at a flow rate of 0.5 mL/min. CRIg-deficient 
mice (C57Bl/6 background) were generously 
provided by Genentech. V4m119 nanobodies were 
generated and produced as described previously [33].  
Synthesis of (±)-H3RESCA-HSA 
A solution of (±)-H3RESCA-tetrafluorophenyl 
ester ((±)-H3RESCA-TFP, 80 µL, 5.64 x 10-6 moles) in 
DMSO was added in a 15-molar excess to a solution of 
human serum albumin (1.5 ml, 3.7609 x 10-7 moles, 
CAF-DCF, Brussels, Belgium) in 0.05 M sodium 
bicarbonate pH 8.6, and the mixture was incubated for 
2 h at rt. The conjugate was purified by gel filtration in 
sodium acetate buffer (0.1 M, pH 4.5, PD-10 column, 
GE Healthcare Bio-Science AB), and the concentration 
of (±)-H3RESCA-HSA was determined spectrophoto-
metrically at 280 nm (Nanodrop 2000, Thermo Fisher 
scientific). The purified product was analyzed by SEC. 
UV detection of the eluate was performed at 280 nm. 
The chelator-to-protein ratio was estimated by 
ESI-TOF-HRMS analysis.  
Radiosynthesis and purification of 
(±)-[18F]AlF(RESCA)-HSA 
After production in a cyclotron, [18F]F− was 
separated from [18O]H2O by trapping on a SepPak 
Light Accel plus QMA anion exchange cartridge (Cl− 
form; Waters). The cartridge was washed with water 
(3 mL, HPCE grade, Sigma-Aldrich), [18F]F− (3.9 GBq) 
was eluted from the cartridge with an aqueous 
solution of sodium chloride 0.9% (0.3 mL, 
Mini-Plasco, solution for injection, B. Braun, Diegem, 
Belgium), and the eluate was diluted with water (0.45 
mL, HPCE grade, Sigma-Aldrich). This [18F]F− 
solution (250 µl, 1.25 GBq) was added to 25 µL of 2 
mM aluminum chloride (AlCl3) in sodium acetate 
buffer (0.1 M, pH 4.5). The solution was incubated at 
rt for 5 min to form {Al18F}2+. A solution of 
(±)-H3RESCA-HSA (0.5 mL, 75 nmoles) in sodium 
acetate buffer (0.1 M, pH 4.5) was added to the freshly 
prepared {Al18F}2+ solution, and was incubated at 
room temperature (20-22 °C) for 12 min. The pH of the 
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final reaction mixture was checked, and was found to 
be pH 4.6. After incubation, the mixture was purified 
by gel filtration with phosphate buffered saline (PBS, 
0.1 M pH 7.4, PD-10 column, GE Healthcare 
Bio-Science AB). Radiochemical yield was calculated 
based on the amount of radioactivity eluted from the 
column relative to the starting activity of [18F]F−. 
Radiochemical identity and purity were assessed by 
SEC. The identity of the main compound was 
confirmed using non-radioactive HSA as reference 
material. 
Synthesis of (±)-H3RESCA-NbV4m119  
A solution of (±)-H3RESCA-TFP (23 µl, 1.4294 x 
10-6 moles) in DMSO was added in 12-molar excess to 
a solution of NbV4m119 (2.5 ml, 1.1912 x 10-7 moles,) 
in 0.05 M sodium bicarbonate pH 8.6, and the mixture 
was incubated for 3 h at room temperature. The 
conjugate was purified by gel filtration with a sodium 
acetate buffer (0.1 M, pH 4.5, PD-10 column, GE 
Healthcare Bio-Science AB), and the concentration of 
(±)-H3RESCA-NbV4m119 was determined 
spectrophotometrically at 280 nm (Nanodrop 2000, 
Thermo Fisher scientific) using the corrected 
extinction coefficient (ε = 35,425 M-1cm-1). Analysis of 
the purified compound was performed by SEC. The 
chelator-to-protein ratio was estimated by 
ESI-TOF-HRMS analysis.  
Radiosynthesis and semi-automated 
purification of 
(±)-[18F]AlF(RESCA)-NbV4m119  
[18F]F- was separated from [18O]H2O by trapping 
on a SepPak Light Accel plus QMA anion exchange 
cartridge (Cl- form; Waters). The cartridge was 
washed with water (3 mL, HPCE grade, 
Sigma-Aldrich), [18F]F- was eluted from the cartridge 
with an aqueous solution of sodium chloride 0.9% (0.3 
mL, Mini-Plasco, solution for injection, B. Braun), and 
the eluate was diluted with water (2.7 ml, HPCE 
grade, Sigma-Aldrich). The [18F]F- solution (0.5 ml) 
was added to 12.5 µL of 2 mM aluminum chloride 
(AlCl3) in sodium acetate buffer (0.1 M, pH 4.5). The 
solution was incubated at rt for 5 min to form 
{Al18F}2+. A solution of (±)-H3RESCA-NbV4m119 (1.5 
mL, 0.55 mg/ml) in sodium acetate buffer (0.1 M, pH 
4.5) was added to the freshly prepared {Al18F}2+ 
solution and the mixture was incubated at ambient 
temperature (20-22 °C) for 12 min. After incubation, 
the mixture was purified using four Hitrap desalting 
columns in series (GE Healthcare Bio-Science AB) 
using sodium phosphate buffer (0.01 M, pH 7.4, 0.14 
M NaCl) as eluent at a flow rate of 1 mL/min. A UV 
detector and 3-inch NaI(Tl) radioactivity detector 
were coupled in series to be able to collect the purified 
product and to calculate the radiochemical yield. The 
collected fraction was filtered through a 0.22-µm filter 
(Millex-GV, 13 mm, Merck KGaA, Darmstadt, 
Germany), and diluted with sodium phosphate buffer 
(0.01 M, pH 7.4, 0.14 M NaCl). Radiochemical identity 
and purity were assessed by SEC and by 
radio-LC-HRMS. The identity of the main compound 
was confirmed using unlabeled NbV4m119 as 
reference material. 
In vitro stability studies 
A volume of 100 µL of purified 
(±)-[18F]AlF(RESCA)-HSA (22 MBq) or 
(±)-[18F]AlF(RESCA)-NbV4m119 (24 MBq) was added 
to freshly isolated rat plasma (1 mL). The mixtures 
were incubated at 37 °C and analysed at 1, 2, 3, and 4 
h after the start of incubation by SEC.  
Biodistribution and microPET studies with 
(±)-[18F]AlF(RESCA)-HSA and 
(±)-[18F]AlF(RESCA)-NbV4m119 
Quantification of radioactivity for 
biodistribution studies was performed using an 
automated gamma counter equipped with a 3-inch 
NaI(Tl) well crystal coupled to a multichannel 
analyser, mounted in a sample changer (Perkin Elmer 
1480 Wizard 3q). Counts were corrected for 
background radiation, physical decay and counter 
dead time. Animals were housed in individually 
ventilated cages in a thermo-regulated (~22 °C), 
humidity-controlled facility under a 12h-12h 
light-dark cycle, with access to food and water ad 
libitum. All animal experiments were conducted 
according to the Belgian code of practice for the care 
and the use of animals, after approval from the 
university animal ethics committee. 
The biodistribution study of (±)-[18F]AlF 
(RESCA)-HSA was carried out in healthy female 
Wistar rats (body weight: 187-225 g) at 1 h, 3 h, and 6 h 
post injection (p.i.; n = 4/time point). Rats were 
injected with (±)-[18F]AlF(RESCA)-HSA (2-7.5 MBq, 
17-62 µg) via a tail vein under anesthesia (2.5% 
isoflurane in O2 at 1 L/min flow rate), and sacrificed 
by decapitation at above specified time points. The 
biodistribution study of (±)-[18F]AlF(RESCA)- 
NbV4m119 was carried out in healthy male C57BL/6 
mice (body weight: 22-26 g) at 1 h and 3 h p.i. (n = 
3/time point) or in CRIg-deficient mice (CRIg-/-, 
C57BL/6 background, body weight: 20-23 g) at 3 h p.i. 
(n = 3/time point). Mice were injected with freshly 
filtered (0.22 µm, Millipore) (±)-[18F]AlF(RESCA)- 
NbV4m119 (7-11 MBq, 8-13 µg ) via a tail vein under 
anesthesia (2.5% isoflurane in O2 at 1 L/min flow 
rate), and sacrificed by decapitation at above specified 
time points. Blood and major organs were collected in 
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tared tubes and weighed. The radioactivity in blood, 
organs, and other body parts was counted using an 
automated γ-counter. Results are presented as 
standardized uptake values (SUV; tissue activity 
(MBq/g)/[injected dose (MBq)/body weight (g)]).  
Small animal whole-body PET imaging was 
performed using a FOCUSTM 220 microPET scanner 
(Concorde Microsystems, Knoxville, US), and PMOD 
software (v 3.2, PMOD Technologies, Zürich, 
Switzerland) was used to analyze the images. The 
animals were kept under gas anaesthesia during the 
entire procedure (2.5% isoflurane in O2 at 1 L/min 
flow rate). A whole-body PET image of a healthy rat 
was obtained 180 min after intravenous injection of 
(±)-[18F]AlF(RESCA)-HSA (96 MBq, 798 µg). A 60-min 
dynamic microPET scan was performed on a healthy 
male C57BL/6 mouse (body weight: 24 g) and 
CRIg-deficient mouse (CRIg-/-, C57BL/6 background, 
body weight: 23 g) simultaneously. The scan was 
started immediately after intravenous injection of 
sterile filtered (0.22 µm, Millipore) 
(±)-[18F]AlF(RESCA)-NbV4m119 (11 MBq, 13 µg).  
Synthesis of (±)-H3RESCA-PEP04314 and 
H2NOTA-PEP04314 
Five mg of lyophilized PEP04314 (0.71 µmol, 
Affibody AB, Solna, Sweden) was added to 0.5 mL of 
0.2 M ammonium acetate buffer (pH 7.5), and the 
solution was added to a reaction vial containing 0.4 
mg (0.72 µmol) of (±)-H3RESCA-maleimide or 
maleimide-mono-amide-NOTA (Macrocyclics, Plano, 
Tx, USA). The reaction mixture was kept at room 
temperature for 90 min before being transferred to an 
ultracel 3K centrifugal filter (Merck) containing 3 mL 
of and 0.1 M ammonium acetate buffer (pH 4) and 
centrifuged at 4000 rpm for 90 min. The flow-through 
was discarded, and 4 mL of fresh 0.1 M ammonium 
acetate buffer (pH 4) was added. The filter was then 
centrifuged again for 90 min, and the flow-through 
was discarded. Purified (±)-H3RESCA-PEP04314 or 
H2NOTA-PEP04314 was collected via reverse spin in 1 
mL of 0.1 M ammonium acetate buffer (pH 4.5), and 
stored at -70 °C in 100 µL aliquots prior to use. Purity 
of the final product was determined via a Waters 
Acquity LC/MS system equipped with a Waters 
Xselect CSH C18 column (250 mm ×10 mm, 130 Å) at a 
flow rate of 5 mL/min using a gradient of EtOH 
(10-40% over 15 min) and 0.1% formic acid. 
Radiosynthesis 
(±)-[18F]AlF(RESCA)-PEP04314 and 
[18F]AlF(NOTA)-PEP04314  
A SepPak Light Accel plus QMA anion exchange 
cartridge (HCO3- form; Waters) containing 
[18F]-fluoride was first washed with 1.5 mL of 
ultrapure water (Water Ultra Trace Elemental 
Analysis Grade, Fisher Chemical, Pittsburgh, USA), 
and then [18F]-fluoride was eluted with 1.0 mL of 0.4 
M KHCO3. An aliquot of 100 μL of the eluted 
[18F]-fluoride solution was added to a reaction vial 
containing 10 μL acetic acid, 50 μL AlCl3 solution (2 
mM in 0.1 M NaOAc buffer, pH 4), and 125 μL 0.1 M 
NaOAc pH 4. The solution was incubated for 2 min at 
room temperature prior to addition of 0.5 mg 
(±)-H3RESCA-PEP04314 or H2NOTA-PEP04314 in 400 
µL of a 1:1 solution of ethanol and 0.1 M NaOAc pH 4. 
The reaction mixture was heated for 15 min at 37 °C 
for (±)-H3RESCA-PEP04314 and at 100 °C for 
H2NOTA-PEP04314. After heating, the reaction 
mixture was transferred to a vial containing 0.7 mL of 
0.1% formic acid, and mixed and purified by HPLC on 
a Waters Xselect CSH C18 column (250 mm ×10 mm, 
130 Å) at a flow rate of 5 mL/min using a gradient of 
EtOH (10-40% over 15 min) and 0.1% formic acid. The 
peak corresponding to (±)-[18F]AlF(RESCA)-PEP04314 
or [18F]AlF(NOTA)-PEP04314 was collected and 
transferred to a sterile vial using normal saline as a 
rinse to give (±)-[18F]AlF(RESCA)-PEP04314 or 
[18F]AlF(NOTA)-PEP04314. Specific activity and 
radiochemical purity were determined via a Waters 
Acquity LC/MS system on a Waters Xselect CSH C18 
column (250 mm ×10 mm, 130 Å) at a flow rate of 5 
mL/min using a gradient of EtOH (10-40% over 15 
min) and 0.1% formic acid and a β-RAM Model 4 
radio-HPLC detector (IN/US Systems, Brandon, FL, 
USA).  
PET/CT studies with 
(±)-[18F]AlF(RESCA)-PEP04314 and 
[18F]AlF(NOTA)-PEP04314 in non-human 
primates 
PET studies were conducted in healthy adult 
rhesus monkeys (n=4, rhesus monkey A-D, weight 
7.6 ± 1.8 kg). All procedures were conducted in 
accordance with the guidelines of the Institutional 
Animal Care and Use Committee of Merck (West 
Point, PA) and guidelines for the care and use of 
mammals in neuroscience and behavioral research 
(National Research Council 2003). Animals were 
housed in temperature- and humidity-controlled 
rooms in fully AAALAC (Association for Assessment 
and Accreditation of Laboratory Animal Care) 
accredited facilities and fed a commercially prepared 
high protein monkey diet (Lab Diet no. 5045, PMI 
Nutrition International, Brentwood, MO); water was 
offered ad libitum. Fresh fruits and vegetables were 
provided daily and animal housing rooms were 
maintained on a twelve hour light/dark cycle. 
Animals were fasted and initially anesthetized 
with ketamine (10 mg/kg IM), and then maintained 
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under anesthesia using IV propofol (5 mg/kg 
induction, 0.6 mg/kg/min maintenance). Following 
the initial induction with propofol, the animal was 
intubated and ventilated with medical grade 
compressed air at ~10 mL/breath/kg and 23 
respirations per minute. Monkeys were instrumented 
with a temperature probe, a pulse oximeter and an 
end tidal CO2 monitor. End tidal CO2 was maintained 
at 40 ± 2 mm Hg, with body temperature maintained 
between 37–38 °C using a T-pump warming pump 
(Gaymar Industrial, Orchard Park, NY) with 
K-module heating pads (Harvard Apparatus, 
Holliston, MA) 
PET data were acquired on a Siemens Biograph 
64 TruePoint PET/CT scanner (Siemens Medical 
Solutions, Malvern, PA).The PET scanner was 
cross-calibrated with the dose calibrator using an 18F 
cylinder according to the manufacturer's standard 
operating procedures. Following a whole body CT 
scan used to correct for photon attenuation and 
scatter, 29-149 MBq ( 9-48 µg) of 
(±)-[18F]AlF(RESCA)-PEP04314 (n=3; n=1 in rhesus 
monkey A, n=1 in rhesus monkey B, n=1 in rhesus 
monkey C) or [18F]AlF(NOTA)-PEP04314 (n=6; n=2 in 
rhesus monkey A, n=2 in rhesus monkey B, n=2 in 
rhesus monkey D) was injected as a 2-min bolus IV. A 
whole body dynamic emission scan was acquired for 
180 minutes, encompassing five fields of view (24 
static frames). Venous samples to measure blood 
levels of radiotracer were obtained throughout the 
scan. Following PET data acquisition, a whole body 
CT with contrast (~3 ml Omnipaque/kg) was 
obtained.  
PET data were reconstructed using the 
vendor-suppled iterative method with 4 iterations 
and 8 subsets. CT-based attenuation and scatter 
correction were carried out as implemented by the 
camera manufacturer. Regions of Interest (ROIs) were 
drawn for liver, kidney cortex, heart blood pool, 
salivary glands, bladder, lung, and muscle using both 
the PET and CT images to guide ROI placement, and 
time activity curves (TACs) were calculated. Bone 
ROIs were drawn on the lumbar spine. Results are 
presented as standardized uptake values (SUV; tissue 
activity (MBq/cm3)/[injected dose (MBq)/body 
weight (g)]). Additional ROIs were drawn to 
encompass all of the bladder and kidney, and these 
were compared to the total radioactivity measured in 
the image to calculate the percentage injected dose 
(%ID) for each organ. Radiotracer levels in venous 
blood samples were fit to a bi-exponential clearance 
curve, and alpha and beta clearance half-lives in blood 
were estimated.  
Statistical analysis 
Quantitative data are expressed as mean ± 
standard deviation (STDEV) unless stated otherwise. 
Means were compared using the unpaired two-tailed 
Student t-test. Values were considered statistically 
significant for P < 0.05. 
Results and Discussion 
(±)-[18F]AlF(RESCA)-Human serum albumin 
The best method to assess the in vivo stability of a 
chelate is to attach it to a suitable vector that is slowly 
cleared from plasma and thus remains in circulation 
for an extended period of time. Human serum 
albumin (HSA, 66.5 kDa) is a heat-sensitive globular 
protein (melting temperature, Tm, of 71°C at 0.5 
mg/ml) [34] with a primary sequence made up of 585 
amino acid residues, and is the most abundant protein 
in human plasma (3.5-5 g/dL) [35]. It accounts for 
about 70% of the plasma colloid osmotic pressure. Its 
high solubility, stability and plasma half-life of 
approximately 16-18 h make HSA the ideal vector to 
evaluate the stability of the Al18F-chelate in vivo. 
Moreover, the Al18F-labeled construct can potentially 
be used for PET blood pool imaging applications [36]. 
HSA possesses 59 lysine residues that can be 
used for the introduction of chelators via reaction of 
ɛ-amino groups with an excess of (±)-H3RESCA-TFP 
(Figure S1). (±)-H3RESCA-TFP ester was efficiently 
conjugated to HSA providing (±)-H3RESCA-HSA 
with a chelator-to-protein ratio of 3, estimated by 
ESI-TOF-HRMS analysis, and no aggregates or 
degradation products were detected (Figure S2). 
(±)-H3RESCA-HSA was labeled directly with 
[18F]{AlF}2+ and a good radiochemical yield (RCY 
52-63%) was achieved using mild reaction conditions 
(rt, 12 min, pH 4.6) compatible with the structural and 
functional integrity of proteins. 
(±)-[18F]AlF(RESCA)-HSA was purified using a 
disposable size-exclusion cartridge, providing the 
final product in high radiochemical purity, as 
assessed by size-exclusion chromatography 
(Figure 2).  
This method provided higher radiochemical 
yields in considerably shorter overall synthesis time 
than other radiofluorination strategies such as the 
prosthetic group approach using [18F]F-Py-TFP 
described by Basuli et al. [36] and the Cu(I)mediated 
1,3-dipolar [3+2]cycloaddition reaction reported by 
Ramenda et al. [37] (Table 1). (±)-[18F]AlF(RESCA)--
HSA showed excellent stability in vitro. After 4 h 
incubation in rat plasma at 37 °C, 92% of the 
Al18F-tracer was still intact as assessed by size 
exclusion chromatography (Figure S3).  
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Figure 2. Synthesis and radiolabeling of (±)-H3RESCA-HSA with [18F]{AlF}2+. (±)-H3RESCA-TFP ester was conjugated to HSA providing 
(±)-H3RESCA-HSA. (±)-[18F]AlF(RESCA)-HSA was prepared in high RCY and RCP, as assessed by size-exclusion chromatography (SEC), in less than 30 min (starting 
after elution of fluorine-18 from the anion exchange QMA cartridge). SEC-radio-chromatogram of purified (±)-[18F]AlF(RESCA)-HSA with a retention time of 28.5 
min. HSA = human serum albumin (PDB ID:1E7H), rt = room temperature (20-25°C), RCY = radiochemical yield (calculated based on the amount of radioactivity 
eluted from disposable desalting column relative to the starting activity of [18F]F−), RCP = radiochemical purity.  
Table 1. Comparison of different radiofluorination methods for labeling the heat-sensitive protein HSA.  
Method (±)-[18F]AlF(RESCA)-HSA [18F]F-Py-HSA [36] Cu(I)mediated 1,3-dipolar [3+2]cycloaddition [37] 
RCY* 52-63% (n=3) 18-35% (n=30) 15-20% 
RCP > 98% > 98% > 95% 
Synthesis time** < 30 min 90 min 120 min 
Tb 8.6 h (in rats) 4.8 h# (in rats) 31 min (in mice) 
RCY: radiochemical yield; RCP: radiochemical purity; Tb: blood biological half-life 
*Calculated based on the amount of radioactivity eluted from disposable desalting column relative to the starting activity of [18F]F−**Starting from [18F]F- # Data for 
[18F]F-Py-RSA (rat serum albumin) 
 
Biodistribution of (±)-[18F]AlF(RESCA)-HSA in 
rats showed high retention in blood with SUV: 11.8 ± 
0.6, 10.1 ± 0.7, and 8.0 ± 0.1 at 1 h, 3 h, and 6 h, 
respectively (Figure 3A, Table S1). Blood data points 
were fitted with a one- component exponential 
equation (y = 12.75e(-0.08x); R² = 0.9998), from which the 
blood biological half-life (Tb) was calculated to be 8.7 
h (Figure S4). This indicates that the introduction of 
RESCA residues into HSA and subsequent 
radiolabeling using the Al18F-method did not alter the 
structural and functional integrity of HSA. In contrast, 
the radiolabeling method using a Cu(I)mediated 
1,3-dipolar [3+2]cycloaddition significantly affected 
functional integrity of HSA, resulting in a Tb of only 
31 minutes [37]. Fluorine-18 in the form of fluoride 
and also [18F]{AlF}2+ are known to accumulate in bone 
[38, 39]. Bone is a highly vascular tissue [40], so this 
might explain the observed bone uptake at 1 h p.i. 
However, only minor increase in bone uptake was 
observed over time, indicating high in vivo stability of 
the Al18F-labeled protein conjugate. Moreover, 
(±)-[18F]AlF(RESCA)-HSA showed favorable 
properties for PET blood pool imaging applications. A 
whole body PET image of a healthy rat 180 min after 
intravenous injection of (±)-[18F]AlF(RESCA)-HSA is 
shown in Figure 3B. The ventricles of the heart and 
the peripheral vasculature are well visualized. Other 
organs can be observed but retain lower 
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concentrations of fluorine-18 than the central 
vasculature. The tissue concentrations in the 
microPET study are consistent with the ex vivo 
biodistribution results at comparable time points.  
 (±)-[18F]AlF(RESCA)-Nanobody 
Nanobodies (Nb, VHH) are heat-sensitive 
antigen-binding fragments derived from 
heavy-chain-only antibodies occurring naturally in 
Camelid species and can be considered as magic bullets 
for immuno-PET imaging [41]. Nanobodies bind their 
antigens very fast and specifically with high affinity in 
vivo, whereas unbound nanobody is rapidly cleared 
from blood by the kidneys [42]. Using nanobodies 
labeled with a positron emitting radionuclide, high 
contrast PET images can be acquired as early as 1 hour 
after tracer administration [43]. This early imaging 
allows the use of short-lived PET radionuclides such 
as fluorine-18. Xavier et al. recently reported 
successful 18F-labeling of HER2-targeting nanobodies 
using the prosthetic group [18F]SFB [44]. The same 
method was used by Blykers et al. and Bala et al. for 
radiofluorination of nanobodies targeting the 
macrophage mannose receptor (MMR) [45] and the 
vascular cell adhesion molecule (VCAM1) [46], 
respectively. 
However, this multistep synthesis is laborious, 
and only limited yields of purified radiolabeled 
product were obtained with moderate apparent molar 
radioactivity (Table 2). We have evaluated the 
Al18F-method for radiolabeling of the nanobody 
NbV4m119 [47], targeting the complement receptor of 
the Ig superfamily (CRIg) [48]. CRIg has a 
pronounced expression on Kupffer cells, which are 
resident liver macrophages. Moreover, it has been 
shown that CRIg is more abundant in rheumatoid 
arthritis (RA) synovial tissue than in normal 
synovium [33]. Consequently, CRIg is a promising 
marker to monitor changes in Kupffer cell dynamics 
[49] and for specific molecular imaging of RA, 
allowing non-invasive quantification of joint 
inflammation [33].  
Characterization of a radiolabeled nanobody is 
important in order to confirm that the derivatization 
and radiolabeling procedure does not affect the 
nanobody integrity. We have therefore explored 
radio-liquid chromatography in combination with 
high-resolution mass spectrometry (radio-LC-HRMS) 
to analyze NbV4m119 before and after derivatization 
with (±)-H3RESCA-TFP ester. The theoretical average 
neutral molecular mass ([M]) of unlabeled NbV4m119 
is 14577.85 Da [M] (calculated for C643H950N188O196S4), 
and the observed molecular mass after deconvolution 
was 14577.61 ± 0.02 Da [M] (Figure S5). We also 
observed the presence of a deamination product with 
an observed molecular mass of 14560.76 ± 0.02 Da 
(calculated for C643H947N187O196S4 [M]: 14560.82). This 
deamination product was expected and can be formed 
spontaneously during manipulation and storage of 
the protein. 
 
 
Figure 3. Biodistribution and PET imaging of rats after intravenous injection of (±)-[18F]AlF(RESCA)-HSA. Biodistribution (A) of 
(±)-[18F]AlF(RESCA)-HSA in rats at 1 h, 3 h, and 6 h p.i. (n=4/group) and whole-body PET image (B) of a healthy rat 180 min after intravenous injection of 
(±)-[18F]AlF(RESCA)-HSA (greyscale SUV (g/ml): max, white; min, black) White arrows indicate ventricles of the heart. Results of biodistribution are presented as 
standardized uptake values (SUV; tissue activity (MBq/g)/[injected dose (MBq)/body weight (g)]). Blood data points were fitted with a one- component exponential 
equation: y = 12.75e(-0.08x); R² = 0.9998, blood biological half-life (Tb) = 8.66 h.  
 Theranostics 2017, Vol. 7, Issue 11 
 
 
http://www.thno.org 
2933 
Table 2. Comparison of two radiofluorination methods for labeling of nanobodies  
Method Al18F-RESCA [18F]SFB [44] [18F]SFB [45] [18F]SFB [46] 
Target CRIg HER2 MMR VCAM-1 
Nanobody V4m119 2Rs15d 3.49 sdAb cAbVCAM-1–5 
RCY 35-53%* (n=3) 5-15%** (n=3) 5-15%** / 
RCP > 98%  > 98% > 97% > 99% 
Synthesis time# < 35 min 180 min 180 min 180 min 
GBq/µmol ##  80-85 17-33 10-30 / 
Overall batch activity 2-2.2 GBq 0.2- 0.5 GBq / / 
RCY: radiochemical yield; RCP: radiochemical purity  
*Calculated based on the preparative chromatogram and relative to radioactivity of [18F]F-/[18F]{AlF}2+ **Calculated based on the amount of radioactivity eluted from 
disposable desalting column relative to the starting activity of [18F]F− #Starting from [18F]F- ##Apparent molar radioactivity at the end of purification 
 
 
NbV4m119 possesses five lysine residues in its 
amino acid sequence, therefore several lysine groups 
can react with the (±)-H3RESCA-TFP active ester via 
the free amino functionalities (Figure S6). 
(±)-H3RESCA-TFP ester was efficiently conjugated to 
NbV4m119 providing (±)-H3RESCA-NbV4m119 with 
a chelator-to-protein ratio of 1.5, estimated by 
ESI-TOF-HRMS analysis, and no aggregates or 
degradation products were observed (Figure S7). The 
theoretical average neutral molecular masses for 
single and dual conjugation are 14979.26 Da [M] 
(calculated for C664H973N189O203S4) and 15397.70 Da 
[M] (calculated for C685H999N191O210S4), respectively. 
The observed molecular masses for 
(±)-H3RESCA-NbV4m119 after deconvolution were 
14979.35 ± 0.02 Da and 15397.69 ± 0.02 Da [M], 
respectively.  
(±)-H3RESCA-NbV4m119 was labeled with 
[18F]{AlF}2+, achieving good radiochemical yields 
using mild conditions and the crude reaction mixture 
was purified using four Hitrap desalting columns in 
series yielding the purified batch (±)-[18F]AlF 
(RESCA)-NbV4m119 (Table 2 and Figure 4). 
(±)-[18F]AlF(RESCA)-NbV4m119 was analyzed with 
radio-RPLC-HRMS and SEC, eluting at a retention 
time of 5.6 min and 26.9 min, respectively (Figure S8 
and Figure 4) to check the radiochemical purity of the 
radiolabeled nanobody. No aggregation or 
degradation products were observed. The 
radiofluorination method provided higher 
radiochemical yields, higher overall batch activity and 
higher apparent molar radioactivity in considerably 
shorter overall synthesis time than the prosthetic 
group approach using [18F]SFB (Table 2). Analysis 
with SEC revealed that 96% of the Al18F-tracer was 
still intact after 6 h incubation in the storage buffer 
(Figure S9), and 91.5% of the Al18F-tracer was still 
intact after 3 h incubation in rat plasma at 37 °C, 
indicating excellent in vitro stability of 
(±)-[18F]AlF(RESCA)-NbV4m119 (Figure S10).  
Since the molecular size of nanobodies is below 
the threshold for renal glomerular filtration (<60 kDa), 
nanobodies are generally cleared quickly from blood, 
primarily via renal clearance. Only 0.20 ± 0.02 and 0.13 
± 0.02 SUV of the radioactivity was observed in blood 
after 1 h and 3 h p.i. respectively, indicating fast blood 
clearance (Table S2). It is known that nanobodies are 
efficiently reabsorbed in the renal proximal tubuli, 
and Gainkam et al. showed elegantly that the megalin 
receptor plays an important role in this mechanism 
using megalin-knockout mice [50]. Kidney retention is 
also significantly affected by the presence of a 
hexahistidine tag, which is genetically inserted in the 
structure of NbV4m119 for the purpose of 
immobilized metal ion affinity chromatography 
purification [50].  
As expected, high uptake in kidneys (SUV: 37.6 ± 
4.5) was observed at 1 h p.i. Figure S11 shows an ex 
vivo autoradiogram of a renal tissue slice of a naive 
WT mouse injected with (±)-[18F]AlF(RESCA)- 
NbV4m119 and sacrificed at 1 h p.i. The radioactivity 
is mainly concentrated in the renal cortex indicating 
that the kidney retention may be caused by tubular 
reabsorption and subsequent internalization. 
Remarkably, at 3 h p.i. kidney uptake was decreased 
drastically (SUV: 8.9 ± 2.3) with a corresponding 
fraction being excreted with the urine, strongly 
indicating that resulting (radio)catabolites are 
non-residualizing. Urine analysis shows the presence 
of mainly radiometabolites of (±)-[18F]AlF(RESCA)- 
NbV4m119, confirming the hypothesis of renal 
metabolism followed by elimination of the catabolites 
via the urine (Figure S12-S13). This high rate of in vivo 
degradation was also reported previously for 
99mTc-labeled nanobodies targeting the epidermal 
growth factor receptor (EGFR). In this study the 
authors found that only 10% of 99mTc-labeled 
nanobody in urine was intact at 1 h p.i. indicating that 
this degradation is specific for nanobodies rather than 
dependent on the radiolabeling method [50].  
Zheng et al. investigated CRIg mRNA levels in 
collagen-induced arthritis (CIA) mice to determine 
whether this marker is expressed homogeneously in 
the body or specifically in certain tissues during 
inflammation [33]. High CRIg mRNA levels were 
found in liver (the CRIg receptor has a pronounced 
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expression on CD11bintermediate F4/801 Kupffer cells in 
the liver) and low or undetectable quantities in bone 
marrow, lymph nodes, spleen and lungs. In 
accordance with these results (±)-[18F]AlF(RESCA)- 
NbV4m119 showed high uptake in liver (SUV: 2.3 ± 
0.2, liver-to-muscle ratio of 33 ± 2.1) at 3 h p.i. in 
healthy mice, but low uptake in other organs (Figure 
5A). In CRIg-/- mice no specific uptake of 
(±)-[18F]AlF(RESCA)-NbV4m119 could be observed in 
the liver (SUV: 0.27 ± 0.1, P < 0.001) at 3 h p.i., 
indicating excellent in vivo CRIg specificity of the 
tracer. This demonstrates that the Al18F-RESCA 
labeling method does not affect the functional 
integrity of nanobodies.  
Higher kidney uptake in the CRIg-/- mice at 3 h 
p.i compared with the kidney uptake in the WT mice 
at 3 h p.i. (P < 0.005) may be explained by the lower 
liver uptake in CRIg-/- mice, resulting in higher 
availability of [18F]AlF-RESCA-NbV4m119 towards 
the renal elimination pathway. It is important to 
minimize residence time of 
(±)-[18F]AlF(RESCA)-NbV4m119 in plastic syringes to 
avoid aggregation, which might result in increased 
lung uptake. Probably, aggregation over time in these 
syringes explains the relative high variation in lung 
uptake seen in the biodistribution study. Aggregation 
of proteins is a common problem and might be related 
to this specific nanobody or labeling method. To 
overcome this issue, different agents can be added to 
the final formulation buffer that promote protein 
solubility (e.g. 0.1% w/v polysorbate 80) [51].  
Although we showed excellent in vitro stability 
of (±)-[18F]AlF(RESCA)-NbV4m119 in rat plasma, the 
biodistribution study showed an increase of bone 
uptake over time, indicating minor levels of 
demetallation and/or defluorination of the 
compound (SUV: 0.6 ± 0.1 and 1.0 ± 0.3 at 1 h and 3 h 
p.i., respectively). One should consider the harsh 
environment in kidney lysosomes as a possible 
explanation for the observed elevated bone uptake. 
Indeed, after glomerular filtration, nanobodies are 
internalized and transported to lysosomes [50]. Here, 
(±)-[18F]AlF(RESCA) may be degraded, and as a result 
[18F]{AlF}2+ and/or [18F]F- could be recycled back into 
circulation, resulting in increased bone uptake values. 
Non-specific bone accumulation might compromise 
the utility of this tracer for noninvasive quantification 
of joint inflammation in vivo.  
 
 
Figure 4. Synthesis and radiolabeling of (±)-H3RESCA-NbV4m119 with [18F]{AlF}2+. (±)-H3RESCA-TFP ester was conjugated to NbV4m119 providing 
(±)-H3RESCA-NbV4m119. (±)-[18F]AlF(RESCA)-NbV4m119 was prepared in high radiochemical yield. Purification was accomplished with SEC using 4 Hitrap 
desalting columns in series, affording highly pure (±)-[18F]AlF(RESCA)-NbV4m119 in less than 35 min (starting after elution of fluorine-18 from the anion exchange 
QMA cartridge). SEC Radio-chromatogram of purified (±)-[18F]AlF(RESCA)-NbV4m119 eluting with a retention time of 26.9 min. rt = room temperature (20-25 °C), 
RCY = radiochemical yield (calculated based on the preparative chromatogram and relative to radioactivity of [18F]F-/[18F]{AlF}2+), RCP = radiochemical purity. 
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Figure 5. Biodistribution and PET imaging of WT and CRIg-/- mice after intravenous injection of (±)-[18F]AlF(RESCA)-NbV4m119 A: 
Biodistribution of (±)-[18F]AlF(RESCA)-NbV4m119 in wild-type mice (WT) and CRIg-/- mice (CRIg-/-) at 3 h p.i (n=3/group). Biodistribution results are presented as 
standardized uptake value (SUV; tissue activity (MBq/g)/[injected dose (MBq)/body weight (g)]). **P < 0.005***P < 0.001 B: Coronal microPET images. Summed 
images (30-60 min p.i., time weighted average) performed on naive WT and CRIg-/- mice.  
 
Nevertheless, the calculated bone uptake is 
limited and might be species-dependent. Whole-body 
PET imaging clearly showed specific uptake of 
(±)-[18F]AlF(RESCA)-NbV4m119 in the liver, whereas 
no liver uptake was observed in the CRIg knockout 
mice, confirming high specificity for CRIg (Figure 5B). 
In vivo PET imaging did not show major bone uptake 
after 1 h and high liver-to background images were 
obtained, indicating favorable in vivo imaging 
properties of (±)-[18F]AlF(RESCA)-NbV4m119.  
 [18F]AlF-RESCA-Affibody  
Affibody molecules are non-immunoglobulin--
based scaffold proteins characterized by high target 
specificity and binding affinity (Kd in the 
low-nanomolar to picomolar range) [52, 53]. These 
small proteins have been generated against different 
cancer-associated molecular targets and have been 
labeled with different radionuclides (68Ga, 18F, 64Cu, 
99mTc, and 111In) suitable for immuno-PET and SPECT 
[54-59]. As for nanobodies, the half-life of fluorine-18 
perfectly matches the fast pharmacokinetics of 
affibody molecules [60]. Indeed, the small size of 
fluorine-18 labeled affibody molecules is responsible 
for fast clearance, providing high contrast images 
within one to three hours after injection. Furthermore, 
introduction of an unpaired cysteine residue at the 
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c-terminus of the protein allows site-specific 
conjugation of chelators or radiolabeled groups via 
maleimide-thiol reactions, avoiding heterogeneous 
tracer populations.  
To show the feasibility of radiolabeling affibody 
molecules using the Al18F-RESCA method, and to 
further investigate the in vivo stability of the 
(±)-[18F]AlF(RESCA)-complex, we radiolabeled a 
generic affibody and conducted PET/CT studies in 
healthy non-human primates. In general, affibodies 
are considered to be heat-stable. However, Da Pieve et 
al. labeled a NOTA-derivatized affibody targeting 
HER3 with [18F]AlF using standard one-pot-reaction 
conditions (pH 4, 100 °C for 15 min) [29]. The reported 
radiochemical conversion and the apparent molar 
radioactivity of the radioconjugate were 38.8 ± 5.8% 
(non-decay corrected) and 6.0−11.9 GBq/μmol, 
respectively. Unfortunately, thermal degradation of 
the radioconjugate was observed, compromising the 
final yield of the reaction. As shown by Heskamp et 
al., good to excellent yields can also be obtained at 
90°C for labeling of affibodies that are more sensitive 
[61]. Nevertheless, direct radiolabeling at low 
temperature (<40°C) using the Al18F-RESCA method 
could provide an interesting alternative to avoid 
possible thermal degradation. 
As a proof of concept, we successfully 
derivatized affibody molecules (PEP04314, also 
known as ZHER2:2891) targeting HER2, exploiting 
site-specific maleimide-thiol reactions with 
(±)-H3RESCA-maleimide to afford (±)-H3RESCA- 
PEP04314. As a control, we also derivatized affibody 
molecules site-specifically with maleimide-mono- 
amide-NOTA to afford H2NOTA-PEP04314. The 
purity of the final products was determined with 
LC/MS (Figure S14). (±)-H3RESCA-PEP04314 and 
H2NOTA-PEP04314 were labeled with [18F]{AlF}2+ in 
radiochemical yields of respectively 20 ± 7% (n=4) and 
8 ± 6% (n=4). Labeling conditions for both compounds 
were identical (15 min, pH 4, 50% v/v ethanol), except 
the reaction temperature was 37 °C for 
(±)-H3RESCA-PEP04314 and 100 °C for 
H2NOTA-PEP04314. For this particular affibody 
(PEP04314), no thermal degradation products were 
observed, even after 15 minutes incubation at 100 °C. 
The crude reaction mixtures were purified using 
preparative RP-HPLC to give (±)-[18F]AlF(RESCA)--
PEP04314 or [18F]AlF(NOTA)-PEP04314 in high 
radiochemical purity (> 98% for both compounds) 
and with apparent molar radioactivity of respectively 
23.2 ± 3.4 GBq/µmol and 21.6 ± 5.4 GBq/µmol at the 
end of purification. Total synthesis time, starting from 
[18F]F-, was less than 30 minutes for both compounds. 
PET/CT studies in healthy male non-human primates 
were performed to evaluate the distribution profile 
and in vivo stability of both (±)-[18F]AlF(RESCA)- 
PEP04314 (n=3) and [18F]AlF(NOTA)-PEP04314 (n=6).  
Preclinical studies have shown that the nature of 
the chelator might have a significant effect on the 
biodistribution of affibody molecules. However this 
effect is difficult to predict [54]. The attachment of the 
macrocyclic chelator, NOTA, to affibody molecules 
involves one of the carboxylic groups of the chelator. 
As a result, only two carboxyl groups remain 
available for chelation of [18F]{AlF}2+, forming a 
neutral complex. In contrast, the RESCA ligand 
conjugated to affibody molecules has three carboxylic 
groups available for chelation of [18F]{AlF}2+, resulting 
in a complex with a negative net charge. This net 
charge might shift elimination more to renal clearance 
and affect kidney retention. On the other hand, the 
more lipophilic nature of RESCA derivative (due to 
the presence of a trans-cyclohexyl building block and 
an additional phenyl ring) in comparison with NOTA 
could shift the elimination of the radiolabeled 
affibody to hepatic clearance.  
PET/CT images of (±)-[18F]AlF(RESCA)--
PEP04314 and [18F]AlF(NOTA)-PEP04314 in a healthy 
rhesus monkey, with the corresponding time-activity 
curves and chemical structures, are shown in Figure 6. 
Tissue uptake values (SUV120-180 min) of both 
compounds are shown in Table S3. Similar 
distribution profiles were observed for both tracers 
with slightly slower blood clearance for 
(±)-[18F]AlF(RESCA)-PEP04314. Radiotracer levels in 
venous samples were fit to a bi-exponential clearance 
curve, and alpha and beta clearance half-lives in blood 
were calculated to be respectively 0.08 ± 0.05 h and 
1.09 ± 0.23 h for [18F]AlF(NOTA)-PEP04314 and 0.04 ± 
0.01 h and 2.70 ± 0.43 h for (±)-[18F]AlF(RESCA)--
PEP04314. The sum of percentage injected dose (%ID) 
in kidneys and urinary bladder (average 120-180 min 
p.i) was 28.8 ± 2.4 %ID for (±)-[18F]AlF(RESCA)--
PEP04314 and 29.9 ± 3.7 %ID for [18F]AlF(NOTA)--
PEP04314. This indicates that the difference in net 
charge and lipophilicity of the chelator seem to 
compensate each other, resulting in a similar renal 
clearance pattern for both compounds.  
Higher liver uptake was observed for 
(±)-[18F]AlF(RESCA)-PEP04314 at early time points, 
probably due to the slower blood clearance (Figure 6). 
However, significantly lower retention in kidney 
cortex was observed for (±)-[18F]AlF(RESCA)--
PEP04314 (standardized uptake value 120-180 min 
after tracer administration (SUV120-180 min) 32.5 ± 8.2) 
than [18F]AlF(NOTA)-PEP04314 (SUV 120-180 min: 56.8 ± 
11.0), and higher accumulation of 
(±)-[18F]AlF(RESCA)-PEP04314 in the bladder was 
also observed in the PET/CT images. The %ID120-180 min 
in bladder was 10.6 ± 0.8 %ID for 
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(±)-[18F]AlF(RESCA)-PEP04314 and only 3.8 ± 1.0 %ID 
for [18F]AlF(NOTA)-PEP04314. The use of 
residualizing radiometals, including [18F]AlF(NOTA) 
complexes [25], results in extended retention of 
radioactivity in kidneys because these stable 
radiocomplexes are not able to diffuse out of the 
proximal tubuli cells. This may cause high radiation 
burden to the kidneys, hinder diagnostic accuracy, 
and limit therapeutic applications. Compared to 
[18F]AlF(NOTA)-PEP04314, (±)-[18F]AlF(RESCA)--
PEP04314 shows less activity accumulating in the 
kidneys due to faster clearance to the bladder. 
Nonetheless, retention in kidneys is still high 
compared to non-residualizing 18F-labeling strategies 
for affibody molecules such as the prosthetic group 
approach using [18F]FBEM [62]. The residualizing 
effect is not only important regarding kidney 
retention, but might also occur in target cells of 
interest (e.g. cancer cells) if there is a high rate of 
internalization. In tumor cells the residualizing effect 
is beneficial, as tumor uptake will be higher and last 
longer.  
Importantly, only minor bone uptake was 
observed for both tracers, with slightly higher values 
for (±)-[18F]AlF(RESCA)-PEP04314 (SUV120-180 min 2.3 ± 
0.7) than [18F]AlF(NOTA)-PEP04314 (SUV120-180 min 1.0 
± 0.3), indicating high in vivo stability of both tracers 
in rhesus monkeys. The increasing bone uptake 
observed for (±)-[18F]AlF(RESCA)-PEP04314 over time 
indicates that the Al18F-complex formed with the 
macrocyclic chelator NOTA shows somewhat higher 
in vivo stability than the Al18F-complex formed with 
the acyclic chelator RESCA, confirming the trade-off 
between reactivity of the chelators towards 
[18F]{AlF}2+ and the in vivo stability of the resulting 
complexes.  
 
 
Figure 6. PET/CT imaging of rhesus monkey after intravenous injection of (A) (±)-[18F]AlF(RESCA)-PEP04314 and comparison with (B) 
[18F]AlF(NOTA)-PEP04314. Summed PET/CT images (120-180 min p.i., time weighted average) performed on healthy rhesus monkey, same animal for both 
compounds (rhesus monkey A). Structures of (C) (±)-[18F]AlF(RESCA)-PEP04314 and (D) [18F]AlF(NOTA)-PEP04314. Time activity curves (TAC) of different organs 
after intravenous injection of (E) (±)-[18F]AlF(RESCA)-PEP04314 (n=3) and (F) [18F]AlF(NOTA)-PEP04314 (n=6), data are presented as average standardized uptake 
values (SUV; tissue activity (MBq/cm3)/[injected dose (MBq)/body weight (g)]) ± SEM.  
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Conclusions 
Fluorine-18 is currently the radionuclide of 
choice for PET because of its favorable nuclear decay 
characteristics and high production capacity. In this 
study, we show that the Al18F-method using the 
recently developed chelator RESCA provides an 
efficient one-step approach to radiolabel 
heat-sensitive biomolecules at low temperature (< 
37°C). We successfully labeled human serum albumin 
with excellent radiochemical yields in less than 30 
minutes and confirmed in vivo stability of the 
Al18F-labeled protein in rats. Moreover, we efficiently 
labeled nanobodies targeting the Kupffer cell marker 
CRIg and performed µPET studies in healthy and 
CRIg deficient mice to demonstrate that the proposed 
radiolabeling method does not affect the functional 
integrity of the protein. Finally, an affibody targeting 
HER2 (PEP04314) was labeled site-specifically, and 
the distribution profile of (±)-[18F]AlF(RESCA)--
PEP04314 in a rhesus monkey was compared with 
that of [18F]AlF(NOTA)-PEP04314 using whole-body 
PET/CT. The total synthesis time (starting from 
[18F]F-) for all compounds was less than 35 minutes, 
which is considerably shorter than for other 
radiofluorination methods. Additionally, in vivo PET 
imaging in rats, mice, and non-human primates 
showed excellent imaging properties for all tracers. 
This new optimized radiolabeling method can be 
considered a breakthrough in fluorine-18 
radiochemistry. It is easy to implement and can be 
generically applied for the development of numerous 
new fluorine-18 labeled heat-sensitive biomolecules. 
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